Investment Analysts’ Weekly Ratings Changes for Myriad Genetics (MYGN)

Several brokerages have updated their recommendations and price targets on shares of Myriad Genetics (NASDAQ: MYGN) in the last few weeks:

• 11/20/2024 – Myriad Genetics was downgraded by analysts at StockNews.com from a “buy” rating to a “hold” rating.
• 11/18/2024 – Myriad Genetics had its price target lowered by analysts at Morgan Stanley from $32.00 to $21.00. They now have an “equal weight” rating on the stock.
• 11/12/2024 – Myriad Genetics was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating.
• 11/11/2024 – Myriad Genetics had its price target lowered by analysts at Piper Sandler from $30.00 to $24.00. They now have a “neutral” rating on the stock.

Myriad Genetics Stock Up 0.6 %

MYGN traded up $0.10 during trading on Wednesday, reaching $16.27. 179,875 shares of the stock were exchanged, compared to its average volume of 743,075. The stock has a market cap of $1.48 billion, a P/E ratio of -12.52 and a beta of 1.93. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.73 and a current ratio of 1.90. The stock’s 50 day moving average price is $22.02 and its two-hundred day moving average price is $24.42. Myriad Genetics, Inc. has a twelve month low of $14.72 and a twelve month high of $29.30.

Insider Transactions at Myriad Genetics

In other Myriad Genetics news, Director Heinrich Dreismann sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $27.05, for a total transaction of $270,500.00. Following the completion of the sale, the director now directly owns 121,648 shares in the company, valued at $3,290,578.40. This trade represents a 7.60 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Paul J. Diaz sold 15,000 shares of the stock in a transaction that occurred on Friday, October 11th. The stock was sold at an average price of $22.93, for a total value of $343,950.00. Following the transaction, the chief executive officer now owns 962,378 shares in the company, valued at approximately $22,067,327.54. This trade represents a 1.53 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 71,012 shares of company stock worth $1,900,485 in the last ninety days. Insiders own 2.10% of the company’s stock.

Institutional Investors Weigh In On Myriad Genetics

A number of institutional investors have recently modified their holdings of the business. Vanguard Group Inc. boosted its holdings in Myriad Genetics by 0.8% in the 1st quarter. Vanguard Group Inc. now owns 10,035,708 shares of the company’s stock valued at $213,961,000 after purchasing an additional 81,475 shares during the period. American International Group Inc. boosted its stake in shares of Myriad Genetics by 6.8% in the first quarter. American International Group Inc. now owns 47,331 shares of the company’s stock valued at $1,009,000 after buying an additional 3,011 shares during the period. CANADA LIFE ASSURANCE Co grew its holdings in shares of Myriad Genetics by 7.4% during the 1st quarter. CANADA LIFE ASSURANCE Co now owns 103,498 shares of the company’s stock worth $2,204,000 after purchasing an additional 7,123 shares in the last quarter. Lazard Asset Management LLC grew its stake in Myriad Genetics by 74.6% during the first quarter. Lazard Asset Management LLC now owns 21,143 shares of the company’s stock worth $449,000 after buying an additional 9,036 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD increased its holdings in Myriad Genetics by 13.4% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 53,568 shares of the company’s stock valued at $1,143,000 after buying an additional 6,337 shares during the period. Institutional investors own 99.02% of the company’s stock.

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.